Analyst Jeet Mukherjee of BTIG maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), retaining the price target of $69.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jeet Mukherjee’s rating is based on promising initial data from Arvinas Holding Company’s ARV-102, a LRRK2 degrader, which demonstrated significant degradation of LRRK2 and modulation of related biomarkers in healthy volunteers. The study showed dose-dependent reductions in LRRK2 and associated biomarkers, indicating a strong pharmacokinetic and pharmacodynamic profile. The safety data was also favorable, with no serious adverse events reported, which adds to the confidence in ARV-102’s potential.
Looking forward, the anticipation of similar positive outcomes in upcoming trials involving Parkinson’s patients further supports the Buy rating. The potential of ARV-102 in addressing central nervous system diseases, combined with its promising early results, positions Arvinas favorably in the market. Additionally, the valuation approach using a 12% discount rate and 1% terminal growth rate reflects a positive long-term outlook for the company.